Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

Gianfranco Ferraccioli, Josef S. Smolen, Monika M. Schoels, Norihiro Nishimoto, Ferdinand C. Breedveld, Gerd R. Burmester, Maxime Dougados, Paul Emery, Cem Gabay, Allan Gibofsky, Juan Jesus Gomez-Reino, Graeme Jones, Tore K. Kvien, Miho Murakami, Neil Betteridge, Clifton O. Bingham Iii, Vivian Bykerk, Ernest H. Choy, Bernard Combe, Maurizio CutoloWinfried Graninger, Angel Lanas, Emilio Martin-Mola, Carlomaurizio Montecucco, Mikkel Ostergaard, Karel Pavelka, Andrea Rubbert-Roth, Naveed Sattar, Marieke Scholte-Voshaar, Yoshiya Tanaka, Michael Trauner, Gabriele Valentini, Kevin L. Winthrop, Maarten De Wit, Désirée Van Der Heijde

Risultato della ricerca: Contributo in rivistaArticolo in rivista

88 Citazioni (Scopus)

Abstract

Since approval of tocilizumab (TCZ) for treatment of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), interleukin 6 (IL-6) pathway inhibition was evaluated in trials of TCZ and other agents targeting the IL-6 receptor and ligand in various RA populations and other inflammatory diseases. This consensus document informs on interference with the IL-6 pathway based on evidence and expert opinion.
Lingua originaleEnglish
pagine (da-a)482-492
Numero di pagine11
RivistaEARD
Volume72
DOI
Stato di pubblicazionePubblicato - 2013
Pubblicato esternamente

Keywords

  • interleukin-6
  • rheumatoid arthritis

Fingerprint

Entra nei temi di ricerca di 'Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions'. Insieme formano una fingerprint unica.

Cita questo